SemaThera, Inc. logo

SemaThera, Inc.

SemaThera develops novel inhibitors of semaphorin 3A (SEMA3A) for the prevention and reversal of retinal vascular diseases such as diabetic retinopathy (DR) and diabetic macular edema (DME). SEMA3A is a soluble protein that promotes vascular leakage, retinal inflammation, apoptosis and prevents vascular regeneration. SEMA3A levels rise in the early stages of DME, while VEGF levels are still as low as in non-diabetic controls. Its levels are significantly elevated in the vitreous of patients with DME, proliferative diabetic retinopathy and exudative age-related macular degeneration. Inhibiting SEMA3A with SemaThera’s biological traps has shown robust pre-clinical efficacy in several disease models.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://semathera.com
Founded2016
Disease Focus
Development Stage
STOCK CODENon Listed
Address
800-1 Westmount Square, H3Z 2P9
Montreal
Canada
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/semathera-inc” connections=”true” suffix=””]